Recent product introductions from Camber include aripiprazoe (Abilify), lamivudine/zidovudine (Combivir), montelukast (Singulair), pantoprazole (Protonix); raloxifene (Evista), rizatriptan (Maxalt); sildenafil (Revatio), valsartan (Diovan) and zolmitriptan (Zomig).
Camber's commitment to consumers is to bring the highest-quality generics to the market to improve quality of life through cost-effective medications. Its impressive growth is tied to quality, service and teamwork, according to president Kon Ostaficiuk. He explains that the company has a simple product strategy--to capitalize on its core strengths to deliver maximum profitability to its customers.
"Our growth begins with a commitment by each individual in our company to never lose sight of the needs of our customers," says Ostaficiuk. "From sales to pricing, to customer service, everyone is pulling in the same direction. We know we have to earn our customers' business every day and in every way: So if it means developing a customized program for a particular partner or staying late on a holiday weekend to make sure all our orders are shipped, it's really just part of the culture here at Camber."
Camber has been recognized as one of the top 15 pharmaceutical companies in overall dispensed prescriptions and No. 1 in growth with an almost 20% increase in 2014, according to IMS Health. The company's comprehensive line of products comprises a wide range of therapeutic categories including antiretrovirals, antivirals, anticonvulsant, antiulcerants, antineoplastics, cardiovascular drugs, antibacterials, antidepressants and anti-diabetics.
Camber is a fully integrated international pharmaceutical company that maintains quality and integrity in all products, from API manufacturing to finished dosage. The company is a wholly owned subsidiary of Hetero Drugs, based in Hyderabad, India. Hetero is a global pharmaceutical, research and development company with an emphasis on API production and manufacturing of finished dosage forms.
Invagen, an associated company, offers a substantial amount of Camber products made in the United States. Collectively, Hetero, Invagen and Camber use over 1 million square feet of warehouse, distribution and manufacturing space.
Camber's global resources include facilities and joint ventures in the U.S., India, South America, Spain and the Middle East; over 400 scientists in API and finished dosage R&D; 11 API facilities (six of which are Food and Drag Administration approved); more than 100 DMFs filed; a presence in over 100 countries; and total control of its supply chain.
The company has also launched a new over-the-counter medication division called Camber Consumer Care. It will focus on the pain, allergy, sleep and cough/cold categories.
"We believe our current success, great reputation and strong existing customer relationships will give us a good opportunity to break into and thrive in the competitive O-T-C marketplace," states Ostaficiuk.
CAMBER PHARMACEUTICALS, INC.
1031 Centennial Ave.
Piscataway, N.J. 08854
Key contact: KON OSTAFICIUK President
Phone: (732) 529-0430